Bionest

The Rise of the Chief Digital Officer in Pharma Companies

Chief Digital Officer (CDO) is the latest title to become a standard within the pharmaceutical company C-suite, with Takeda, Bayer, GlaxoSmithKline, Novartis, Merck, Sanofi and others all making such appointments in recent years. As we’ve written before, this addition to the pharma senior management team reflects the growing importance of digital to pharma, which encompasses...

Bionest

Applying Precision Medicine to Neuropsychiatric Disorders

Cancers were once looked upon as specific diseases, often defined by their tissue of origin, and drug treatments primarily aimed to kill rapidly growing tumor cells before harming slower growing normal ones. The result was often limited drug efficacy, accompanied by debilitating side-effects. Today, however, the growing understanding of the biology and genetics of particular...

Bionest

New Excitement About Antibody-Drug Conjugates in Cancer

The ability to target malignant cells without damage to surrounding healthy ones has been a long-sought goal in cancer drug development. Antibody-drug conjugates (ADCs) have been investigated as one such solution aimed at delivering more targeted therapies. ADCs — an approach first envisioned by Paul Ehrlich in the early 20th century — combine the targeting...

Bionest

Blockchain and Pharmaceutical Supply Chain Security

Blockchain is a method to securely store digital information and create an accurate, verifiable, distributed record of individual transactions that is confidential, traceable and virtually uneditable. The first practical use of blockchain technology enabled bitcoin and other cryptocurrency transactions. Today, blockchain is being tested by a number of pharmaceutical companies, drug wholesalers, and at least...